<DOC>
	<DOCNO>NCT01204450</DOCNO>
	<brief_summary>RATIONALE : Drugs temsirolimus valproic acid may stop growth tumor cell block enzymes need cell growth . Valproic acid may also stop growth solid tumor block blood flow tumor . PURPOSE : This phase I trial study side effect best dose temsirolimus give together valproic acid treat young patient relapse neuroblastoma , bone sarcoma , soft tissue sarcoma .</brief_summary>
	<brief_title>Temsirolimus Valproic Acid Treating Young Patients With Relapsed Neuroblastoma , Bone Sarcoma , Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To identify maximum-tolerated dose temsirolimus combination valproic acid highly pretreated pediatric patient refractory solid tumor . Secondary - To estimate objective response rate patient treat regimen . - To estimate progression-free survival patient treat regimen . - To explore association tumor IGF-IR , mTOR expression , HDAC , autophagy biomarkers , serum level temsirolimus , valproate , VEGF-A toxicity disease response . - To evaluate ability select member division newly develop North Carolina-based pediatric oncology consortium cooperate clinical trial . OUTLINE : This multicenter , dose-escalation study temsirolimus . Patients receive temsirolimus IV 30-60 minute day 1 , 8 , 15 , 22 oral valproic acid* 3 time daily day 1-28 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Blood sample collect baseline periodically study pharmacokinetic VEGF-A study . Tumor tissue sample archive biopsy also analyze IGF-IR , mTOR expression , HDAC , autophagy biomarkers . After completion study therapy , patient follow every 3 month 1 year , every 4 month 2 year , every 6 month 2 year . NOTE : * Doses valproic acid titrate begin 3-7 day prior start temsirolimus achieve plasma level 75-100 µg/mL .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor original diagnosis , include follow : Neuroblastoma Bone sarcoma ( primary neuroectodermal tumors/ Ewing sarcoma ( PNET/ES ) , osteosarcoma ) Soft tissue sarcoma ( rhabdosarcoma relate tumor ) Histologically confirm relapsed disease highly recommend mandatory Measurable disease accord RECIST Refractory progressive disease ≥ 1 ≤ 4 prior chemotherapy regimens Patients neuroblastoma , PNET/ES , rhabdosarcoma must fail cyclophosphamide/topotecancontaining regimen Stem cell transplantation , include preparative regimen posttransplant immunotherapy , consider 1 regimen PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) 50100 % ( Lansky PS 50100 % ) Life expectancy ≥ 8 week ANC ≥ 750/mm^3 Platelet count ≥ 75,000/mm^3 ( transfusion independent ) Hemoglobin 8.0 g/dL ( may receive RBC transfusion ) Patients tumor metastatic bone marrow allow receive transfusion maintain hemoglobin platelet count Serum creatinine normal Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) OR direct bilirubin &lt; 1.0 mg/dL ( total bilirubin &gt; 2.0 mg/dL ) ALT &lt; 5 time ULN Negative pregnancy test Not pregnant nursing Fertile patient must use effective contraception Families must able give consent English Spanish No allergy H1 antihistamines PRIOR CONCURRENT THERAPY : See Disease Characteristics More 2 week since prior chemotherapy , immunotherapy , radiotherapy recover No concurrent anticonvulsant , include valproic acid No concurrent strong inducer inhibitor CYP3A4 , include grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>